Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling
Alexander J.T. Wood, Arlette M. Vassallo, Marie-Hélène Ruchaud-Sparagano, Jonathan Scott, Carmelo Zinnato, Carmen Gonzalez-Tejedo, Kamal Kishore, Clive S. D’Santos, A. John Simpson, David K. Menon, Charlotte Summers, Edwin R. Chilvers, Klaus Okkenhaug, Andrew Conway Morris
Alexander J.T. Wood, Arlette M. Vassallo, Marie-Hélène Ruchaud-Sparagano, Jonathan Scott, Carmelo Zinnato, Carmen Gonzalez-Tejedo, Kamal Kishore, Clive S. D’Santos, A. John Simpson, David K. Menon, Charlotte Summers, Edwin R. Chilvers, Klaus Okkenhaug, Andrew Conway Morris
View: Text | PDF
Research Article Immunology Infectious disease

C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling

  • Text
  • PDF
Abstract

Critical illness is accompanied by the release of large amounts of the anaphylotoxin, C5a. C5a suppresses antimicrobial functions of neutrophils which is associated with adverse outcomes. The signaling pathways that mediate C5a-induced neutrophil dysfunction are incompletely understood. Healthy donor neutrophils exposed to purified C5a demonstrated a prolonged defect (7 hours) in phagocytosis of Staphylococcus aureus. Phosphoproteomic profiling of 2712 phosphoproteins identified persistent C5a signaling and selective impairment of phagosomal protein phosphorylation on exposure to S. aureus. Notable proteins included early endosomal marker ZFYVE16 and V-ATPase proton channel component ATPV1G1. An assay of phagosomal acidification demonstrated C5a-induced impairment of phagosomal acidification, which was recapitulated in neutrophils from critically ill patients. Examination of the C5a-impaired protein phosphorylation indicated a role for the PI3K VPS34 in phagosomal maturation. Inhibition of VPS34 impaired neutrophil phagosomal acidification and killing of S. aureus. This study provides a phosphoproteomic assessment of human neutrophil signaling in response to S. aureus and its disruption by C5a, identifying a defect in phagosomal maturation and mechanisms of immune failure in critical illness.

Authors

Alexander J.T. Wood, Arlette M. Vassallo, Marie-Hélène Ruchaud-Sparagano, Jonathan Scott, Carmelo Zinnato, Carmen Gonzalez-Tejedo, Kamal Kishore, Clive S. D’Santos, A. John Simpson, David K. Menon, Charlotte Summers, Edwin R. Chilvers, Klaus Okkenhaug, Andrew Conway Morris

×

Figure 1

C5a induces a prolonged defect in neutrophil phagocytosis of bacteria.

Options: View larger image (or click on image) Download as PowerPoint
C5a induces a prolonged defect in neutrophil phagocytosis of bacteria.
(...
(A and B) Isolated neutrophils were pretreated with 100 nM C5a or vehicle control for 60 minutes before incubation with S. aureus (A) or E. coli (B) bioparticles (5 μg/mL). Data are presented as the median phagocytic index for each condition for n = 7 (A) or 6 (B) independent experiments. *P = 0.016 (A) and 0.031 (B) by Wilcoxon’s matched-pairs signed-rank test. (C) Neutrophils were pulsed with C5a (100 nM) or PBS control for the indicated periods of time and then washed 2 times. S. aureus bioparticles (5 μg/mL) were then added and cells were incubated for the indicated time points. Data are presented as the mean plus or minus SD of the phagocytic index of C5a-treated cells relative to their paired vehicle control for n = 5 independent experiments. P < 0.0001 for time and P = 0.0186 for treatment by 2-way ANOVA. ***P = 0.0001 ****P < 0.0001 by Dunnett’s multiple comparison test. (D) Data are presented as the mean plus or minus SD of the percentage of DRAQ7 positive, dead cells for n = 5 independent experiments. P = 0.378 for time and P = 0.349 for treatment by 2-way ANOVA. (E) Anticoagulated whole blood was pretreated with 300 nM C5a or control for the indicated duration before phagocytosis was measured as previously indicated. Data are presented as the mean plus or minus SD of the cumulative phagocytic index for n = 4 independent experiments. P < 0.0001 by 2-way ANOVA, ****P < 0.0001, ***P < 0.001 by Holm-Šidák’s multiple comparisons test. (F) S. aureus bioparticles (15 μg/mL) were incubated with isolated PMNs in the presence of C5a (100 nM) or PBS added at the indicated time points, with time 0 representing the time of addition of S. aureus bioparticles. Experiments proceeded for the indicated time points and phagocytic index quantified. Data are presented as the mean plus or minus SD of the phagocytic index of C5a-treated cells relative to their paired vehicle control for n = 5 independent experiments. P < 0.0001 for time and P = 0.0186 for treatment by 2-way ANOVA. ****P < 0.0001 by Dunnett’s multiple comparisons test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts